“Encore is excited about adding another great product to our portfolio and looking forward to the opportunity to commercialize a new product for the treatment of mild to moderate psoriasis as well as broadening our portfolio outside of atopic dermatitis and acne,” said Robert Moccia, CEO, Encore Dermatology, Inc.
Onkos Surgical, Inc., a specialty medtech company dedicated to advancing innovation for the surgical oncology market announced today that it will launch a new service platform focused on preoperative surgical planning called Precision Oncology. The company will showcase the new platform at the upcoming Musculoskeletal Tumor Society (MSTS) held in Denver, Colorado.
Colorescience®, the leading dermatologist-recommended skin health cosmetics company, has earned a Fall Beauty O-Ward for their new All Calm™ Clinical Redness Corrector SPF 50, launched in August 2017. A first-and-only product created to instantly neutralize redness and soothe sensitive skin, it was created to offer immediate color correction, chemical-free SPF 50 UVA/UVB sun protection, and …
Nutrition 21, LLC is pleased to announce its expanded partnership with American Media, Inc. (AMI) that is dedicated to educating consumers on the benefits of Nitrosigine. Nitrosigine is scientifically engineered to significantly boost nitric oxide levels, a key factor in increasing blood flow to working muscles^ and is formulated to help consumers train longer, harder …
Colorescience®, the leading dermatologist-recommended skin health cosmetics company, is proud to introduce the innovative All Calm™ Clinical Redness Corrector. Formulated for redness, rosacea and sensitive skin, this first-of-its-kind formula instantly calms and soothes skin while its subtle green undertones neutralize redness, and its patent-pending BioSolaceTM complex helps provide ongoing relief from sensitivity and the appearance …
Adele is bringing the firm she co-founded, 1315 Capital, L.P., into the newest round for the cosmetics company that Mary spun off from SkinMedica. Colorescience raised $15-million in Series C financing in a round led by 1315.
Colorescience®, the leading dermatologist-recommended skin health cosmetics company, today announced the successful completion of a $15 Million Series C Preferred Stock financing led by 1315 Capital, L.P., a Philadelphia-based healthcare investment firm that specializes in providing expansion and growth capital to specialty pharmaceutical, medical technology, and healthcare services companies.
Nutrition 21’s patented ingredient combining amylopectin and chromium, brand named Velositol, has attained GRAS (generally recognized as safe) status after an extensive and rigorous review of the scientific dossier and safety data conducted by Intertek Health Sciences, Inc.
Genoptix, Inc., a leading oncology diagnostics laboratory and informatics company, today announced that it offers three diagnostic tests that support immunotherapy decisions for solid tumor cancers.
James Komorowski, MS, CNS, vice president of scientific and regulatory affairs at Nutrition 21, presented the results of three preclinical studies on Nutrition 21’s patented amylopectin and chromium combination ingredient, Velositol, at the ISSN (International Society of Sports Nutrition) conference on June 24th in Phoenix.